🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Focal therapy is emerging as a standard management strategy for select men with intermediate-risk prostate cancer. However, it is not for all men, according to experts who debated the topic at #AUA25. Read our latest feature: renalandurologynews.com/features/focal…

Advanced imaging for #FocalTherapy in intermediate-risk #ProstateCancer. Matt Cooperberg UCSF Helen Diller Family Comprehensive Cancer Ctr and Zach Klaassen Georgia Cancer Center discuss the integration of OnQ™ Prostate assisted Focal One® Robotic HIFU for prostate cancer treatment. #WatchNow > bit.ly/3G0tLP5

Our chapter on HIFU for Prostate Cancer is out now in Interventional Oncology. The published chapter offers a comprehensive overview of HIFU, covering principles, clinical application, and emerging techniques. link.springer.com/rwe/10.1007/97… Dr Andre Abreu Lorenzo Storino Ramacciotti USC Urology

Don't miss key Focal One Robotic HIFU and Focal Therapy talks by Pr. Sébastien Crouzet with experience performing over 3,000 HIFU procedures and Focal Therapy expert [email protected] at the #SRS2025 Annual Meeting in Strasbourg on July 17. You can also stop by the Focal One

use of focal therapy has almost doubled in the US since 2019 urotoday.com/recent-abstrac…

Focal Therapy Finding Its Niche for Intermediate-Risk #Prostate #Cancer renalandurologynews.com/features/focal…

#Salvage #RARP Appears Safe for Recurrent #Prostate #Cancer After #Focal ZZ#Therapy renalandurologynews.com/news/prostate-…

Nanoknife IRE focal therapy, so nice to see this PRESERVE trial finally in print, a monumental and collaborative effort by the Society of Urologic Oncology SUO Clinical Trials Consortium.. a big advancement in care for men with prostate cancer... sciencedirect.com/science/articl… AngioDynamics, Inc.

Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial - ScienceDirect sciencedirect.com/science/articl…

results from the PRESERVE trial show NanoKnife to be a safe & effective treatment for intermediate risk prostate cancer AngioDynamics, Inc. sciencedirect.com/science/articl…

NanoKnife is a safe and effective treatment for intermediate-risk #prostatecancer See the results from the PRESERVE trial 👇 sciencedirect.com/science/articl… As the UK distributor for #NanoKnife we would be keen to discuss the product and how to set up a service. #focaltherapy #urology

📣It’s Here: The PRESERVE Publication The most significant clinical study to date on the NanoKnife System for prostate tissue ablation is now published. 🔍PRESERVE offers prospective, multicenter evidence on intermediate-risk patients and answers the call for data-driven

TULSA is a groundbreaking, minimally invasive outpatient procedure redefining prostate cancer treatment. ❤️‍🩹 This innovative treatment enables patients like Mark Nicholson to avoid traditionally invasive procedures and maintain quality of life. As the first and only hospital in

this comprehensive review of minimally-invasive treatments for prostate cancer shows promising results on outcomes EAU Young Academics pubmed.ncbi.nlm.nih.gov/40491395/

Great to see one of our Chairs of Urology Heer Lab on the cover of the latest Urology Matters TheUrologyFoundation! Discussions about #TRANSFORM, his research programme at Imperial College London and role as Chair of the Scientific and Education Committee at TheUrologyFoundation

Data from the #PRESERVE trial have been published in European Urology, showing that IRE with the NanoKnife System was safe and effective for prostate tissue ablation in patients with intermediate-risk prostate cancer. #pcsm urologytimes.com/view/irreversi…

Vernon had an elevated PSA and was diagnosed with intermediate risk prostate cancer. After consulting with his Urologist Gopal Gupta, MD from Loyola Medicine, Vernon was treated with Focal One, a non-invasive, nonsurgical option in the management of prostate cancer. "After three

FDA Clears Updated #MRI / #Ultrasound Fusion System for Use in Focal Therapy of #ProstateCancer diagnosticimaging.com/view/fda-updat… American College of Radiology ARRS RSNA Society of Abdominal Radiology | SAR Penn Radiology Winship Cancer Institute of Emory University Johns Hopkins Radiology Montefiore Radiology Yale Department of Radiology & Biomedical Imaging Philips Healthcare #radiology #RadRes

#Eur_Urol @Euplatinum Prospective study PRESERVE (n=121). irreversible electroporation tissue ablation for intermediate-risk localized prostate cancer showed 71% negative in-field biopsy rate at 12mo with 12% grade≥3 adverse events. PMID:40685282 pubmed.ncbi.nlm.nih.gov/40685282/

FDA Clears Updated #MRI / #Ultrasound Fusion System for Use in Focal Therapy of #ProstateCancer diagnosticimaging.com/view/fda-updat… American College of Radiology ARRS RSNA Society of Abdominal Radiology | SAR Penn Radiology Montefiore Radiology UVA Radiology Brigham and Women's Radiology Ohio State Radiology Philips Healthcare #radiology #RadRes